Alzheimer's medication how it works ?

One of the most important worldwide challenges are the next generation Alzheimer's disease treatments. New results, candidate therapeutics, and methodological issues will be some of the major worldwide issues discussed at the 2019 CTAD Congress. It will also allow the participants to share their experience on the disease symptoms, and their skills on the dementia treatment. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments. The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. The AD disease process can be minored thanks to non-pharmaceutical trials and that anti-amyloid treatment, as discussed at the 2018 CTAD Congress. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD along with combination therapeutics and phase 3 clinical trials results. Studies on the early stage symptoms will be presented at the 2019 CTAD Congress by the clinical teams. New examples of trials will be highlighted in the 2019 CTAD Congress. Speeding the development of effective Alzheimer's treatment disease is one of the urge of the CTAD 2019 conference. The JPAD Journal of Prevention of Alzheimer's Disease will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including : neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and health economic outcomes.